GlassScriptPhysician profile
Brandy M Dantzer
NPI 1558505131
$17,965.76
in general payments reported to CMS, 2019-2025
49 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,628 · 2022: $4,624 · 2023: $2,861 · 2024: $2,712 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,579 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,578.84 |
| Education | $134.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $6,058.85 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $1,472.02 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,136.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,025.41 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $992.44 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $703.94 | 2021-2025 | Tepezza, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.55 | 2021-2024 | Jardiance |
| Recordati_rare_diseases_inc. | $475.35 | 2021-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $469.41 | 2021-2023 | Farxiga |
| Medtronic, INC. | $453.24 | 2022-2025 | Inpen Smart Insulin Delivery System |
| Mannkind Corporation | $351.58 | 2021-2025 | Afrezza |
| Alexion Pharmaceuticals, INC. | $325.15 | 2022-2025 | Strensiq |
| Antares Pharma, INC. | $279.71 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $276.55 | 2021-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $271.88 | 2021-2025 | Korlym |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.42 | 2022-2025 | |
| Dexcom, INC. | $226.20 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $221.73 | 2021-2023 | Steglujan, Steglatro |
| Insulet Corporation | $206.38 | 2021-2024 | Omnipod |
| Ibsa Pharma INC. | $181.43 | 2021-2025 | Tirosint, Licart, Tirosint |
| Lexicon Pharmaceuticals, INC. | $178.50 | 2023-2024 | Inpefa |
| Pfizer INC. | $155.48 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.66 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $141.12 | 2025 | |
| Esperion Therapeutics, INC. | $140.11 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $136.16 | 2021-2024 | Unithroid |
| Abbvie INC. | $134.82 | 2022-2025 | |
| Amryt Pharma Holdings LTD | $126.66 | 2021-2023 | Mycapssa |
| Radius Health, INC. | $107.09 | 2023-2025 | Tymlos |
| Ascensia Diabetes Care US INC. | $102.92 | 2021-2024 | |
| Kyowa Kirin, INC. | $102.12 | 2023-2025 | Crysvita |
| Eusa Pharma (US) LLC | $95.94 | 2022 | |
| Sequel Med Tech, LLC | $76.65 | 2025 | Twiist |
| Amarin Pharma, INC. | $60.08 | 2021 | |
| Nestle Healthcare Nutrition INC. | $57.95 | 2021-2022 | |
| Grt US Holding, INC. | $40.90 | 2022 | |
| Horizon Therapeutics Plc | $33.21 | 2022-2023 | Tepezza |
| Kowa Pharmaceuticals America, INC. | $33.05 | 2021 | |
| Beta Bionics, INC. | $29.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $23.60 | 2024 | Resmetirom |
| Zealand Pharma US, INC. | $23.03 | 2022 | |
| Averitas Pharma INC. | $20.85 | 2025 | Qutenza |
| Alvogen INC | $20.01 | 2025 | Teriparatide |
| Chiesi USA, INC. | $19.91 | 2025 | Mycapssa |
| Lifescan, INC. | $17.38 | 2023 | |
| Halozyme INC | $16.11 | 2023 | |
| Tolmar, INC. | $15.49 | 2025 | Jatenzo |
| Regeneron Healthcare Solutions, INC. | $14.92 | 2022 | |
| Cequr Corporation | $8.65 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Dantzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.